Glyxambi
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 1310
  • Home
  • Print this page
  • Email this page


 
   Table of Contents      
ONE MINUTE OPHTHALMOLOGY
Year : 2019  |  Volume : 67  |  Issue : 2  |  Page : 195

Just another chalazion?


Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, USA

Date of Web Publication23-Jan-2019

Correspondence Address:
Dr. Carol L Shields
Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA - 19107-5109
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijo.IJO_18_19

Rights and Permissions

How to cite this article:
McLaughlin J, Lally SE, Shields CL. Just another chalazion?. Indian J Ophthalmol 2019;67:195

How to cite this URL:
McLaughlin J, Lally SE, Shields CL. Just another chalazion?. Indian J Ophthalmol [serial online] 2019 [cited 2019 Jun 17];67:195. Available from: http://www.ijo.in/text.asp?2019/67/2/195/250668




  Case Top


A 60-year-old Caucasian male noted a red lesion on the right lower eyelid which was growing over 3 months. He revealed previously treated cancers of the colon, ureter, and skin, all under control without recurrence. He also noted previous eyelid surgery 2 years ago revealing a well-differentiated sebaceous carcinoma. Family history disclosed multiple members with skin and colon carcinomas. On examination of the patient, visual acuity was 20/20 OD and 20/30 OS. There was an elevated, lightly colored cutaneous lesion on the right lower eyelid margin, temporal to the site of the previous biopsy and measuring 6 × 4 × 3 mm.


  What is Your Next Step? Top


  1. Shave biopsy of the lesion and follow up in 3 months.
  2. Wedge resection with immunohistochemical testing for Muir-Torre syndrome (MTS).
  3. Close monitoring with daily applications of hot compresses and topical corticosteroid ointment.
  4. Test for Gorlin–Goltz syndrome and proceed with photodynamic therapy.



  Findings Top


A pentagonal eyelid resection of the mass [Figure 1]a and [Figure 1]b was performed. Histopathology revealed a low-grade sebaceous neoplasm most consistent with sebaceous adenoma. Immunohistochemical testing for DNA mismatch repair proteins in the excised tissue demonstrated normal staining for MLH1 [Figure 1]c and abnormal absence (lack of staining, mutation) for MSH2 [Figure 1]d. These findings were suggestive of underlying MTS.
Figure 1: External photograph showing nodular lesion on the right lower lid margin (a) and invading the tarsus (b). Immunohistochemical staining for DNA mismatch repair proteins revealed normal staining for MLH1 (c) and lack of staining for MSH2 (d), suggestive of Muir-Torre syndrome

Click here to view



  Diagnosis Top


Sebaceous adenoma in the setting of MTS.


  Correct Answer: B. Top



  Discussion Top


MTS is a rare variant of Lynch syndrome found in <1% of the population. This syndrome is clinically suspected by the occurrence of both a visceral cancer, usually involving the colon or genitourinary system, along with cutaneous sebaceous neoplasms. This constellation of neoplasms is typically multiple, occur at an early age, and are generally histopathologically low grade.[1] Colorectal carcinoma is the most common primary malignancy, found in approximately 51% of MTS patients and generally localized proximal to the splenic flexure.[2] Other common internal malignancies include cancer of the endometrium, ovary, and uroepithelium which make up 24% of cases. Mismatch repair gene mutations in MLH1 and MSH2 spawn the development of various neoplasms.[3]

Acknowledgements

Acknowledgment to Dr. Tatyana Millman and Dr. Ralph Eagle for their contributions to histopathology photomicrographs.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Lee JB, Litzner BR, Vidal CI. Review of the current medical literature and assessment of current utilization patterns regarding mismatch repair protein immunohistochemistry in cutaneous Muir–Torre syndrome-associated neoplasms. J Cutan Pathol 2017;44:931-7.  Back to cited text no. 1
    
2.
Schwartz RA, Torre DP. The Muir-Torre syndrome: A 25-year retrospect. J Am Acad Dermatol 1995;33:90-104.  Back to cited text no. 2
    
3.
Jagan L, Zoroquiain P, Bravo-Filho V, Logan P, Qutub M, Burnier J, et al. Sebaceous adenomas of the eyelid and Muir-Torre syndrome. Brti J Ophthalmol 2015;99:909-13.  Back to cited text no. 3
    


    Figures

  [Figure 1]



 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
Case
What is Your Nex...
Findings
Diagnosis
Correct Answer: B.
Discussion
References
Article Figures

 Article Access Statistics
    Viewed7595    
    Printed18    
    Emailed0    
    PDF Downloaded298    
    Comments [Add]    

Recommend this journal